| Worldwide distribution of cytochrome P450 alleles: a meta‐analysis of population‐scale sequencing projects Y Zhou, M Ingelman‐Sundberg, VM Lauschke Clinical Pharmacology & Therapeutics 102 (4), 688-700, 2017 | 595 | 2017 |
| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 274 | 2023 |
| Integrating rare genetic variants into pharmacogenetic drug response predictions M Ingelman-Sundberg, S Mkrtchian, Y Zhou, VM Lauschke Human genomics 12, 1-12, 2018 | 218 | 2018 |
| Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions SU Vorrink, Y Zhou, M Ingelman-Sundberg, VM Lauschke Toxicological Sciences 163 (2), 655-665, 2018 | 181 | 2018 |
| An optimized prediction framework to assess the functional impact of pharmacogenetic variants Y Zhou, S Mkrtchian, M Kumondai, M Hiratsuka, VM Lauschke The pharmacogenomics journal 19 (2), 115-126, 2019 | 128 | 2019 |
| Comprehensive evaluation of organotypic and microphysiological liver models for prediction of drug-induced liver injury Y Zhou, JX Shen, VM Lauschke Frontiers in pharmacology 10, 1093, 2019 | 112 | 2019 |
| Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity VM Lauschke, Y Zhou, M Ingelman-Sundberg Pharmacology & therapeutics 197, 122-152, 2019 | 102 | 2019 |
| Computational methods for the pharmacogenetic interpretation of next generation sequencing data Y Zhou, K Fujikura, S Mkrtchian, VM Lauschke Frontiers in Pharmacology 9, 1437, 2018 | 64 | 2018 |
| The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data Y Zhou, VM Lauschke The Pharmacogenomics Journal 22 (5), 284-293, 2022 | 57 | 2022 |
| Ethnogeographic and inter-individual variability of human ABC transporters Q Xiao, Y Zhou, VM Lauschke Human Genetics 139 (5), 623-646, 2020 | 45 | 2020 |
| Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost‐Effectiveness of Preemptive Pharmacogenetic Testing Y Zhou, K Krebs, L Milani, VM Lauschke Clinical Pharmacology & Therapeutics 109 (1), 160-174, 2021 | 43 | 2021 |
| Pharmacogenomics in the era of next generation sequencing–from byte to bedside LE Russell, Y Zhou, AA Almousa, JK Sodhi, CK Nwabufo, VM Lauschke Drug Metabolism Reviews 53 (2), 253-278, 2021 | 35 | 2021 |
| Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health Y Zhou, VM Lauschke Human Genetics 141 (6), 1113-1136, 2022 | 34 | 2022 |
| Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier Y Zhou, C Dagli Hernandez, VM Lauschke British Journal of Cancer 123 (12), 1782-1789, 2020 | 34 | 2020 |
| Organotypic and microphysiological human tissue models for drug discovery and development—current state-of-the-art and future perspectives S Youhanna, AM Kemas, L Preiss, Y Zhou, JX Shen, SD Cakal, ... Pharmacological Reviews 74 (1), 141-206, 2022 | 33 | 2022 |
| Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences Y Zhou, L Nevosadová, E Eliasson, VM Lauschke Human genomics 17 (1), 15, 2023 | 29 | 2023 |
| Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk E De Mattia, M Silvestri, J Polesel, F Ecca, S Mezzalira, L Scarabel, ... Biomedicine & Pharmacotherapy 154, 113644, 2022 | 29 | 2022 |
| Computational tools to assess the functional consequences of rare and noncoding pharmacogenetic variability Y Zhou, VM Lauschke Clinical Pharmacology & Therapeutics 110 (3), 626-636, 2021 | 29 | 2021 |
| Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk [S] Y Zhou, R Mägi, L Milani, VM Lauschke Journal of lipid research 59 (10), 1987-2000, 2018 | 29 | 2018 |
| Challenges and opportunities associated with rare-variant pharmacogenomics Y Zhou, R Tremmel, E Schaeffeler, M Schwab, VM Lauschke Trends in pharmacological sciences 43 (10), 852-865, 2022 | 28 | 2022 |
Volker LauschkeFull Professor, Karolinska Institutet; Deputy Head, IKPVerified email at ki.se
